Evofem Biosciences, Inc.

EVFM

US30048L3024

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:59:37 24/05/2024 BST			5-day change	1st Jan Change
0.016 ^USD	+14.29%		+10.34%	-75.00%

05-16	Transcript : Evofem Biosciences, Inc. - Special Call
05-15	Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evofem Biosciences, Inc. Provides Sales Guidance for the Fiscal Year 2022

May 04, 2022 at 09:30 pm

Evofem Biosciences, Inc. provided sales guidance for the fiscal year 2022. For the year, the company expects net product sales will be in the range of $30 million to $35 million.

Latest news about Evofem Biosciences, Inc.

Transcript : Evofem Biosciences, Inc. - Special Call	05-15
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-27	CI
Transcript : Evofem Biosciences, Inc. - Special Call	03-27
North American Morning Briefing : Dow Set For New -2-	12-14	DJ
Laidlaw Downgrades Evofem Biosciences to Hold From Buy	12-13	MT
Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Transcript : Evofem Biosciences, Inc. Presents at Virtual Investor Ask the CEO Conference, Oct-24-2023 10:00 AM	24/10/23
Evofem Biosciences, Inc. Provides Sales Guidance for the Third Quarter of 2023	24/10/23	CI
Evofem Biosciences, Inc. announced that it has received $3.504807 million in funding	26/09/23	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/08/23	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Evofem Biosciences, Inc. announced that it has received $0.65 million in funding	03/08/23	CI
Evofem Biosciences, Inc. announced that it has received $1.5 million in funding	02/07/23	CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23/06/23	DJ
Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/06/23	CI
North American Morning Briefing : Stock Futures -2-	16/06/23	DJ
MEI Pharma's Finance Chief Brian Drazba to Step Down; Company Names Justin File as Successor	13/06/23	MT
MEI Pharma Names Justin File as Chief Financial Officer	13/06/23	MT
Evofem Biosciences, Inc. Receives Paragraph IV Certification Notice Letter from Padagis Israel Pharmaceuticals Ltd	05/05/23	CI
Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23	CI
Evofem Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	26/04/23	CI
Evofem Biosciences, Inc. Appoints Ivy Zhang as Secretary	14/04/23	CI
Evofem Biosciences, Inc. Announces CFO Changes	14/04/23	CI

Chart Evofem Biosciences, Inc.

Duration

Period

More charts

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing advanced products to address unmet needs in womenâs sexual and reproductive health. The Companyâs first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Additionally, the Company offers women direct access to Phexxi through its telehealth partner. Using this platform, women can have a telehealth visit with a health care provider (HCP) to determine their eligibility for a Phexxi prescription.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.016

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOFEM BIOSCIENCES, INC.	-75.00%	1.12M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals